QCG
EIGR

Quadrant Capital Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Quadrant Capital Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14
Closed -$4K – 2102
2017
Q1 		$4K Hold
14
– – ﹤0.01% 1435
2016
Q4 		$4K Buy
+14
New +$5.13K ﹤0.01% 1333

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Quadrant Capital Group's EIGR Position: Q2 2017 in Review

Quadrant Capital Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2017, closing a stake of 14 shares — an estimated $4K sold.

Quadrant Capital Group first reported a position in EIGR in Q4 2016 and held it in 2 quarters. The position peaked at $4K in Q1 2017. 39 funds tracked by Wall St. Rank hold EIGR as of Q2 2017.

  • Quadrant Capital Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Quadrant Capital Group sold 14 Eiger BioPharmaceuticals, Inc. shares in Q2 2017, an estimated $4K.
  • Quadrant Capital Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Quadrant Capital Group's Eiger BioPharmaceuticals, Inc. position peaked at $4K in Q1 2017.
  • 39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2017.

Based on Quadrant Capital Group's 13F filing for Q2 2017, filed 15 Aug 2017.